Albendazole Chewable Tablet Dissolution Failure
A manufacturer in Cavite produces albendazole 400 mg chewable tablets for a DOH tender. The formulation contains albendazole 400 mg, microcrystalline cellulose, pregelatinized starch, crospovidone 5%, magnesium stearate 2.5%, and colloidal silicon dioxide; granules are prepared with PVP in water and compressed at 14–18 kp. A validation batch of 100,000 tablets has hardness 15 kp and friability 0.35%, but dissolution at 45 minutes is 62%, against an internal specification of not less than 80% at 45 minutes. The batch is worth PHP 1.2 million and the tender delivery is in 10 days. The QA head asks whether to rework by milling and recompressing, blend with a good batch, or reject. There is no alternative stock.
1. Identify the most probable formulation and process causes of the dissolution failure, and rank them.
Read the worked answer
Albendazole is poorly water-soluble, so dissolution is sensitive to particle wetting, surface area, and tablet porosity. The most probable causes, ranked: (1) magnesium stearate at 2.5% is high and hydrophobic; overblending can coat granules and reduce wettability and dissolution. (2) Compression at 14–18 kp can lower porosity and slow liquid penetration. (3) The PVP granulation may produce dense, poorly wettable granules. (4) Crospovidone 5% may be insufficient for this poorly soluble drug, especially without a surfactant. Confirm by reviewing blending time, magnesium stearate lot, compression force, granule size, and tablet porosity, and by a small DOE varying magnesium stearate (0.5–1%), blending time, compression force, and disintegrant level; test dissolution and hardness.
2. Evaluate the three options-rework by milling and recompression, blending with a good batch, or rejection-under GMP and regulatory standards.
Read the worked answer
Blending with a good batch is unacceptable: it masks an out-of-specification result and creates a non-uniform, unvalidated batch-an adulterated product. Rework by milling and recompression is possible only if there is an approved rework procedure, QA assessment, and data showing dissolution, content uniformity, stability, and chewability are unaffected; rework can further densify granules and worsen dissolution. Rejecting the batch is the defensible default if the root cause is not established, because a chewable deworming tablet with 62% dissolution may under-treat patients. The tender deadline does not justify release. Notify management and the purchaser, and use the batch for investigation, not sale.
3. What control strategy and in-process tests would prevent recurrence?
Read the worked answer
Control strategy: reduce magnesium stearate to 0.5–1.0% and control blending time with a validated endpoint; optimize compression force to a target hardness and porosity range; control granule size and binder addition; consider a wetting agent or surfactant and optimize disintegrant. Add in-process controls for blend uniformity, granule flow, tablet hardness, friability, and porosity; use dissolution as a release test and include stability. Qualify the magnesium stearate and crospovidone suppliers, and trend dissolution by batch.